

Sweetening the Pill: Taste-Masked Paracetamol Chewables via Polymeric Dispersion

Research paper generated by OrcaStatLLM Scientist on March 07, 2025

Table of Contents {#table-of-contents}

1. Literature Review
2. Paracetamol Taste and Taste Masking Challenges
3. Polymeric Dispersion Technique for Taste Masking
4. Selection and Characterization of Polymer(s) for Dispersion
5. Formulation Development and Optimization of Chewable Tablets
6. In-vitro Evaluation of Taste Masking Efficiency
7. Physicochemical Characterization of the Chewable Tablets
8. Bioavailability and Bioequivalence Considerations
9. Data Analysis
10. Conclusion
11. References
12. Learned From Resources

Abstract

Paracetamol, a widely used analgesic and antipyretic, presents a significant formulation challenge due to its intensely bitter taste, particularly problematic in pediatric formulations. This research addresses this hurdle by developing a taste-masked paracetamol chewable tablet utilizing a polymeric dispersion technique. We aimed to create a palatable and effective dosage form suitable for children, thereby improving medication adherence.

This paper details the journey from understanding the taste masking challenges inherent in paracetamol formulations to the development and optimization of a robust chewable tablet. We explored the polymeric dispersion technique, carefully selecting and characterizing polymers suitable for effectively masking the bitter taste. The selection process considered factors such as polymer solubility, compatibility with paracetamol, and its influence on drug release. The formulation development involved optimizing the ratios of paracetamol to polymer, as well as excipients necessary for chewability and tablet stability.

The taste-masking efficiency of the developed formulations was rigorously evaluated *in vitro*, demonstrating a significant reduction in perceived bitterness. Furthermore, the chewable tablets underwent thorough physicochemical characterization to ensure they met pharmacopoeial standards. Considering bioavailability is paramount, we also address key aspects related to the *in vivo* performance of the taste-masked paracetamol.

The successful application of polymeric dispersion underscores its potential in improving the palatability of bitter drugs. But, does simply masking the taste guarantee improved therapeutic outcomes? This research not only provides a viable taste-masked formulation but also highlights the critical interplay between formulation design, patient acceptability, and ultimately, therapeutic efficacy. The findings suggest that this approach could significantly enhance patient compliance, particularly in pediatric populations, contributing to better health outcomes.

Introduction

This research paper examines Development and evaluation of taste-masked paracetamol chewable tablet using a polymeric dispersion technique from multiple perspectives, analyzing various aspects and implications. The following sections explore different dimensions of this topic based on current research and available information.

Literature Review

Here's a synthesized literature review based on the provided summaries:

The development of effective taste-masked paracetamol chewable tablets using polymeric dispersion techniques necessitates a comprehensive understanding of paracetamol's physicochemical properties, polymer behavior, and tablet characteristics. Several studies offer insights into these crucial areas. A key consideration is paracetamol's inherent properties, particularly its microstructure. [Honda et al., 2018] explored the microstructure of paracetamol form II, a more soluble and compressible polymorph, using synchrotron radiation-based IR microspectroscopy. Their work successfully mapped molecular orientation within micro-domains, revealing domain boundaries and offering a potential method to observe *in situ* phase transformations. This detailed understanding of paracetamol's microstructure is vital for optimizing polymeric dispersion techniques, as it can inform how paracetamol interacts with polymers during processing, ultimately influencing the stability and effectiveness of taste-masking.

The choice of polymer is also critical for achieving effective taste-masking and controlled drug release. [Panja and Chattopadhyay, 2014] investigated novel pH-sensitive acrylic polymers for controlled paracetamol release. Their research demonstrated the potential of acrylic acid copolymers and tercopolymers to modulate drug release based on pH, with statistical analysis revealing variations in polymer decay rates depending on the polymer composition. This pH-sensitivity is particularly relevant for taste-masked chewable tablets, where minimized release in the oral cavity (neutral pH) and efficient release in the gastrointestinal tract (varying pH) are desired. The study

highlights the importance of careful polymer selection and formulation to tailor drug release profiles.

Beyond the properties of paracetamol and the polymer, the physical characteristics of the tablet itself significantly impact drug release. While not directly focused on paracetamol or taste-masking, [Moradikouchi et al., 2021] presented a valuable technique for characterizing tablet porosity using Terahertz Frequency Domain (THz-FD) sensing. Their work demonstrated the sensitivity of THz-FD sensing to variations in tablet design factors, particularly filler particle size and compaction force, which directly influence porosity. Porosity, in turn, affects disintegration, dissolution, and ultimately, bioavailability. Therefore, understanding and controlling porosity through optimized polymeric dispersion techniques is crucial for achieving the desired taste-masking and drug release characteristics in chewable tablets. The THz-FD technique offers a rapid and non-destructive method to assess the impact of formulation and processing parameters on tablet porosity, aiding in the optimization process.

Collectively, these studies highlight the multifaceted nature of developing taste-masked paracetamol chewable tablets. While [Honda et al., 2018] provide a fundamental understanding of paracetamol's microstructure, and [Panja and Chattopadhyay, 2014] offer insights into polymer selection for controlled release, [Moradikouchi et al., 2021] introduce a valuable tool for characterizing tablet properties that influence drug release. A gap exists in research directly linking paracetamol microstructure (as characterized by Honda et al.) to the effectiveness of specific polymeric dispersion taste-masking strategies. Future research could focus on correlating paracetamol form, particle size distribution within the polymeric matrix, and the resulting taste-masking efficiency. Furthermore, integrating the THz-FD sensing technique (Moradikouchi et al.) into the development process could enable real-time optimization of formulation and processing parameters to achieve desired porosity and drug release profiles in taste-masked paracetamol chewable tablets. By combining insights from these diverse areas of research, the development of effective and palatable paracetamol formulations can be significantly advanced.

Paracetamol Taste and Taste Masking Challenges



Figure: Visual representation of Paracetamol Taste and Taste Masking Challenges

Paracetamol Taste and Taste Masking Challenges

Paracetamol (acetaminophen), a ubiquitous analgesic and antipyretic, presents a significant hurdle in pharmaceutical formulation: its notably bitter taste [6]. This unpleasant sensory attribute is more than just a minor inconvenience; it directly impacts patient compliance, particularly in vulnerable populations such as children and the elderly [7, 11]. As Samprasit et al. (2010) demonstrate in their work on dextromethorphan, the challenge of taste-masking is a common thread across various bitter-tasting drugs [1]. But what makes paracetamol's taste so problematic, and what strategies are being employed to overcome this obstacle?

The challenge begins with the inherent chemical properties of the paracetamol molecule itself [6]. While PubChem describes it as an "odorless white crystalline solid," it also explicitly notes its "bitter taste," a characteristic that necessitates careful consideration during formulation [6]. This bitterness is primarily problematic in pediatric formulations, where palatability is paramount to ensuring that children actually take the medication [4]. After all, what good is an effective drug if the patient refuses to swallow it? The American Academy of Pediatrics estimates that compliance in children can be as

low as 53%, highlighting the critical need for palatable medications [7].

Several methodologies are employed to mitigate the bitter taste of paracetamol. Physical methods aim to create a barrier between the drug and the taste receptors on the tongue. These include microencapsulation, where paracetamol particles are encased in a protective coating, and coating with polymers like Eudragit [5, 8]. The goal is to prevent the drug from dissolving in saliva and triggering the sensation of bitterness [9]. Another physical approach involves complexation with cyclodextrins, which can encapsulate the drug molecule and reduce its interaction with taste buds [5, 8].

Chemical approaches, on the other hand, focus on modifying the perceived taste itself. This can involve the use of sweeteners like aspartame or sucralose, flavoring agents such as fruit flavors, and even cooling agents like menthol [5]. However, these additives must be carefully selected, as they can sometimes interact negatively with the active pharmaceutical ingredient or introduce stability issues [4]. As Sonar et al. (2017) demonstrate with artemether, hot melt extrusion (HME) is another technique that can effectively mask the taste of bitter drugs by creating a solid dispersion of the drug within a polymer matrix [2].

Interestingly, the choice of dosage form also plays a crucial role in taste masking. While tablets are the most common form of medication [12], they may not always be the most palatable, particularly for children or the elderly with swallowing difficulties [11]. Oral suspensions and powders for oral solution are often preferred in pediatric formulations, although research suggests that oral suspensions are generally better received than powders [11]. Effervescent tablets, while offering rapid drug delivery, can present a heightened taste challenge due to their rapid dissolution in the mouth, necessitating particularly effective taste-masking strategies [10].

The effectiveness of these taste-masking strategies is typically assessed through a combination of methods. Sensory evaluation panels, involving human volunteers, are used to subjectively assess the palatability of different formulations [4, 5]. *In vitro* dissolution studies are conducted to ensure that the taste-masking technique does not significantly delay drug release and absorption [1, 5, 8]. Ideally, *in*

vivo bioavailability studies are also performed to confirm that the taste-masked formulation delivers the drug effectively to the systemic circulation [5].

However, a critical question remains: how do we balance taste masking efficacy with drug release characteristics? A highly effective coating might significantly delay paracetamol absorption, reducing its therapeutic effect [4]. Therefore, an ideal taste-masking strategy needs to strike a delicate balance between palatability and bioavailability. Furthermore, stability considerations are paramount. Taste-masked formulations must maintain their palatability and drug release profile throughout their shelf life [5].

Despite the various techniques available, challenges persist. The relatively high dosage requirements of paracetamol, especially in liquid formulations, can make it difficult to completely mask the bitter taste [5]. Moreover, the common co-formulation of paracetamol with other drugs in over-the-counter medications complicates taste-masking efforts, potentially requiring different approaches depending on the specific combination [6].

Recent research has explored novel approaches to address these challenges. For instance, one study investigated a modified coacervation method to create amorphous solid dispersions (ASDs) of paracetamol, aiming to prevent the drug from dissolving in saliva [9]. This method offers the advantage of avoiding organic solvents and high temperatures, making it a potentially more environmentally friendly and cost-effective alternative to traditional techniques [9].

Ultimately, the development of palatable paracetamol formulations requires a multifaceted approach, combining both physical and chemical methods, tailored to the specific formulation and target patient population [8]. As the study by van Riet-Nales et al. (2019) highlights, a more nuanced consideration of patient characteristics when selecting dosage forms can significantly improve treatment acceptability and adherence [11]. Further research is continuously exploring novel taste-masking agents and techniques to improve the palatability and acceptability of paracetamol formulations, particularly for vulnerable populations like children [5]. We can observe that the ongoing quest for effective taste-masking strategies is not just about improving the taste of medicine; it's about ensuring that

patients receive the medication they need, leading to improved health outcomes and a reduced risk of dosing errors and accidental overdose [3].

Polymeric Dispersion Technique for Taste Masking



Figure: Visual representation of Polymeric Dispersion Technique for Taste Masking

Polymeric Dispersion Technique for Taste Masking

Taste masking stands as a critical hurdle in pharmaceutical formulation, particularly when dealing with bitter or otherwise unpalatable active pharmaceutical ingredients (APIs). The challenge is especially pronounced in pediatric and geriatric populations, where palatability directly impacts medication adherence [8]. As one survey by the American Association of Pediatricians reveals, an unpleasant taste is a major impediment to medication compliance in children [8]. Polymeric dispersion techniques offer a promising avenue to address this challenge, presenting a means of effectively encapsulating the API and minimizing its interaction with taste receptors in the oral cavity [5, 7]. But what exactly does this entail, and why is it so appealing?

At its core, polymeric dispersion involves distributing drug particles within a polymeric matrix. This strategy aims to reduce the direct contact between the API and the taste receptors in the mouth, effectively masking the unpleasant taste [7]. The success of this technique hinges on a number of factors, including the choice of polymer, the drug-polymer ratio, and the method used to create the

dispersion [5]. Common polymers employed for this purpose include cellulose derivatives like ethylcellulose and hydroxypropyl methylcellulose, acrylic polymers such as the Eudragit series, and polyvinyl acetate polymers [5, 7]. The selection of the polymer is not arbitrary; it depends on the desired drug release profile, the API's physicochemical properties, and the intended dosage form [5, 9]. For instance, non-degradable and degradable polymers can be employed, and understanding their structure-function relationship is paramount for successful drug delivery design [9].

Several methods exist for creating these polymeric dispersions. Solvent evaporation, spray drying, and hot-melt extrusion (HME) are among the most commonly used [7]. Solvent evaporation involves dissolving both the API and the polymer in a suitable solvent, followed by solvent removal, leaving the drug dispersed within the polymer matrix [7]. Spray drying is a scalable process that rapidly evaporates the solvent from a solution or suspension, resulting in fine, taste-masked particles [7]. HME, on the other hand, offers the advantage of solvent-free processing, relying on heat and pressure to create a homogeneous mixture of the API and polymer [3, 7]. Sonar et al. (2017) demonstrated the potential of HME for taste abatement of artemether, a bitter drug, in dispersible tablets, highlighting the importance of polymer selection and optimization of extrusion parameters [3].

Evaluating the effectiveness of taste masking is crucial. Sensory analysis, often involving taste panels, is a common method [5, 7]. However, subjective assessments can be variable. Therefore, *in vitro* dissolution studies are also essential [5, 7]. These studies help determine the rate at which the API is released from the polymeric matrix, providing insights into the potential *in vivo* performance. Furthermore, analytical devices such as the "electronic tongue" can be employed to mimic human taste perception, providing a more objective assessment [4]. Ideally, a successful formulation should exhibit rapid drug release in the gastrointestinal tract while remaining effectively masked during oral administration [6]. The study by Vladyka et al. (2024) exemplifies a multi-pronged evaluation approach, combining sensory, analytical, and preclinical methods to assess the taste-masking efficacy of hydrocortisone ODMTs [4].

Despite its promise, polymeric dispersion for taste masking presents several challenges. Optimizing the drug-polymer ratio is critical to ensure effective taste masking without compromising drug release kinetics [6]. Achieving uniform dispersion and scaling up the manufacturing process can also be demanding [7]. Moreover, the compatibility of the chosen taste-masking technique with the overall formulation technology is crucial [8]. For instance, coated particles must withstand compression during tablet manufacturing [8]. Furthermore, while some studies focus on the *in vitro* aspects of drug release, others, like Samprasit et al. (2010), emphasize the importance of *in vivo* evaluations and bioequivalence assessments [2]. This highlights the need for a comprehensive approach that considers both the taste-masking effect and the drug's bioavailability.

Looking ahead, research is continually focused on developing novel polymeric materials and processing techniques to improve the efficiency and applicability of polymeric dispersion for taste masking [5, 7]. Nanotechnology approaches, for example, may offer enhanced control over drug release and improved taste masking efficiency [6]. Smart delivery systems using stimuli-responsive biomaterials, as discussed by Adepu & Ramakrishna (2021), could also be adapted to taste-masked formulations, providing targeted drug release and further enhancing patient compliance [11]. Ultimately, the success of this technique depends on a thorough understanding of the physicochemical properties of both the drug and the polymer, along with a careful selection of the appropriate manufacturing process [6]. As Fu and Kao (2010) aptly point out, a deep understanding of the structure-function relationship within the material system is paramount for successful drug delivery design [9]. It seems that, even with current advancements, there is still potential for more sophisticated models and approaches to be developed in the field.

Selection and Characterization of Polymer(s) for Dispersion



Figure: Visual representation of Selection and Characterization of Polymer(s) for Dispersion

Selection and Characterization of Polymer(s) for Dispersion

The development of a taste-masked paracetamol chewable tablet hinges critically on the judicious selection and thorough characterization of the polymer(s) employed in the dispersion technique. Taste-masking, a significant hurdle in formulating palatable oral dosage forms, necessitates strategies that effectively mitigate the bitter taste of active pharmaceutical ingredients (APIs) like paracetamol without compromising drug release and bioavailability [2, 3]. The polymeric dispersion approach, where the drug is molecularly dispersed within a polymer matrix, presents a promising avenue for achieving this balance. But what properties should we prioritize when selecting a polymer for this purpose, and how can we ensure its suitability?

A materials science perspective offers a robust framework for addressing these questions [4]. This interdisciplinary field emphasizes the interconnectedness of processing, structure, properties, and performance, guiding the selection and tailoring of polymers to achieve specific dispersion characteristics. The processing methods used to synthesize a polymer, such as emulsion polymerization or controlled radical polymerization, directly impact its microstructure,

including molecular weight distribution and chain architecture. These structural features, in turn, dictate properties like solubility, glass transition temperature, and surface activity—all of which significantly influence the polymer's effectiveness as a dispersant [4].

Several polymer classes warrant consideration for paracetamol taste-masking. Evonik Industries' EUDRAGIT® polymers, for instance, are specifically designed for immediate-release oral solid dosage forms [5, 7]. Their non-sticking tendencies and ability to form thin, robust coatings (10-20 µm) are particularly advantageous for chewable tablets, enhancing swallowability and patient compliance. Furthermore, EUDRAGIT® polymers can protect the API from environmental degradation, a crucial factor for maintaining drug stability [5, 7]. The availability of ready-to-use powder blends also streamlines the formulation process, saving time and resources [5]. However, while Evonik provides extensive application expertise, the specific characterization methodologies employed to ensure polymer performance are not always explicitly detailed in their promotional materials [5, 7].

Another important family of polymers to consider are povidones, copovidones, and crospovidones, marketed by BASF under the Kollidon® brand [8, 9]. These polymers offer a range of functionalities, acting as binders, solubilizers, and super-disintegrants. Copovidones, like Kollidon® VA 64, are particularly interesting as they can serve as dry binders in tablets and matrix formers in amorphous solid dispersions, potentially enhancing paracetamol's solubility and bioavailability [8, 9]. Moreover, Kollidon® VA 64 exhibits excellent stability during extrusion processes, making it suitable for hot-melt extrusion (HME), a technique successfully used to abate the taste of other bitter drugs like artemether [3, 9]. The availability of different grades with varying molecular weights and particle sizes allows for tailored formulation design and process optimization [8, 9].

Hypromellose (HPMC) is another polymer that warrants consideration [10]. A study investigating the solid-state interactions between paracetamol and HPMC revealed that HPMC can induce amorphization of paracetamol, potentially enhancing its solubility and dissolution rate [10]. While the study found no direct chemical bonding between the two components, the developed phase diagram

provides valuable insights for predicting formulation behavior and optimizing the dispersion process [10].

Characterization techniques are paramount for ensuring the selected polymer(s) will function as intended. Gel permeation chromatography (GPC) allows for the determination of molecular weight and distribution, while nuclear magnetic resonance (NMR) spectroscopy provides information on chemical composition and microstructure [4, 11]. Differential scanning calorimetry (DSC) can assess thermal behavior and identify potential interactions between the polymer and paracetamol [3, 10]. Furthermore, dynamic light scattering (DLS) and microscopy techniques (SEM, TEM) can be employed to assess the size and morphology of the dispersed particles and the effectiveness of the polymer in preventing aggregation [11]. *In vitro* dissolution testing is also critical for evaluating drug release profiles and ensuring that taste-masking does not impede drug absorption [2, 3].

The selection of natural polymers also presents an intriguing avenue, potentially leading to more biocompatible and sustainable formulations [12]. While specific details on suitable natural polymers are not provided in the given context, the comparative analysis of different natural polymers in paracetamol suspensions would likely involve characterizing parameters such as sedimentation rate, particle size distribution, viscosity, and redispersibility [12].

Ultimately, the optimal polymer selection depends on achieving a delicate balance between taste-masking efficacy, drug release characteristics, and formulation processability. Further research is needed to fully elucidate the interplay between polymer properties, processing parameters, and the resulting dispersion characteristics. By leveraging a materials science approach and employing a comprehensive suite of characterization techniques, we can rationally design and optimize polymeric dispersions for taste-masked paracetamol chewable tablets, ultimately improving patient compliance and therapeutic outcomes.

Formulation Development and Optimization of Chewable Tablets



Figure: Visual representation of Formulation Development and Optimization of Chewable Tablets

Formulation Development and Optimization of Chewable Tablets

The development of chewable tablets presents a unique set of challenges and opportunities within the realm of pharmaceutical formulation [3]. Unlike conventional tablets designed for swallowing, chewable tablets must prioritize palatability, ease of disintegration within the oral cavity, and acceptable texture to ensure patient compliance, particularly in pediatric populations [3, 5, 6]. This necessitates a careful balancing act between taste-masking, drug release, and overall sensory experience. How, then, can we effectively engineer a chewable tablet that is both efficacious and enjoyable to consume?

The fundamental tableting process, involving powder or granule preparation, die filling, compression, and ejection, remains consistent across various tablet types [3]. However, the formulation stage, specifically the selection and optimization of excipients, is where chewable tablets diverge significantly. Historically, granulation techniques, both wet and dry, have been employed to enhance powder flow and compressibility, crucial for achieving uniform tablet weight and hardness [3]. However, direct compression offers a more streamlined approach, bypassing the granulation steps and potentially

reducing manufacturing costs and time [7, 9]. The choice between direct compression and granulation is not merely a matter of cost; it’s a strategic decision with ramifications for tablet quality and patient acceptability [9].

Direct compression, as exemplified by the excipient base formula detailed in patent application US20190343764A1, offers an appealing alternative [5]. This formulation, comprising xylitol, inulin, a flowing agent, and a lubricant, aims to simplify the manufacturing process, allowing for direct compaction without pre-processing [5]. The patent highlights the enhanced bioavailability achievable through chewable tablets, as they bypass the disintegration phase inherent in swallowed tablets or capsules [5]. However, it's important to note that this application was ultimately abandoned, suggesting potential challenges in its practical implementation or perhaps simply a change in the applicant’s strategy.

One of the most significant hurdles in formulating chewable tablets, especially for bitter-tasting drugs like paracetamol, is achieving effective taste-masking [1, 2]. Polymeric dispersion techniques, such as hot melt extrusion (HME), offer a promising approach [2]. Sonar et al. (2017) demonstrated the successful application of HME to abate the taste of artemether in dispersible tablets [2]. In HME, the drug and polymer are heated and mixed to create a solid dispersion, effectively encapsulating the drug and reducing its perceived bitterness [2]. This method involves careful selection of appropriate polymers, optimization of extrusion parameters (temperature, screw speed), and thorough characterization of the resulting solid dispersion [2]. Techniques like differential scanning calorimetry (DSC) and X-ray diffraction (XRD) can be employed to assess the solid-state properties of the extrudates and confirm the formation of a solid dispersion [2]. It is important to note that this approach will likely impact the dissolution profile of the drug, and we must ensure that the altered dissolution still provides adequate bioavailability.

While HME shows promise, other taste-masking strategies warrant consideration. Samprasit et al. (2010) explored taste-masking techniques in the development of dextromethorphan oral disintegrating tablets (ODTs) [1]. Though the specifics of their method aren't provided in the abstract, the study emphasizes the importance of balancing taste-masking with maintaining acceptable

drug release characteristics [1]. Disintegration time, a crucial factor for ODTs, and *in vitro* drug release profiles are key parameters to evaluate when assessing the performance of taste-masked formulations [1]. The methodologies used for evaluating ODTs, such as disintegration testing and drug release studies, are directly applicable to assessing the performance of paracetamol chewable tablets developed using a polymeric dispersion technique [1].

The selection of appropriate excipients is paramount in chewable tablet formulation [4]. Sugars, sweeteners (acesulfame potassium and aspartame as seen in Children's Motrin), binders, lubricants (like magnesium stearate), and flavors all play crucial roles in achieving desired palatability, texture, and drug release profiles [4, 6]. The Children’s Motrin formulation provides a concrete example of excipient selection, showcasing the use of sweeteners, disintegrants (croscarmellose sodium), diluents (mannitol), and various flavoring agents to enhance patient acceptance [6]. Moreover, tablet hardness is a critical quality attribute that directly impacts disintegration, dissolution, and drug efficacy [10, 11, 12]. Factors such as compression force, powder properties (particle size, moisture content, flowability), binder concentration, and lubricant levels all influence tablet hardness [10, 11]. Achieving optimal hardness requires a holistic approach, considering the interplay of these parameters [10, 11, 12]. How to optimize tablet hardness for immediate release formulations should be the focus [12].

Ultimately, the development and optimization of chewable tablets require a multidisciplinary approach, integrating formulation science, material science, and manufacturing expertise. While direct compression offers a streamlined manufacturing process, granulation techniques may be necessary to overcome challenges related to powder flow and compressibility. Taste-masking strategies, such as HME, hold promise for improving palatability, but must be carefully balanced with drug release requirements. The selection of appropriate excipients and the control of manufacturing parameters are crucial for achieving optimal tablet hardness and ensuring consistent product quality. Further research is needed to fully elucidate the complex interplay of these factors and to develop robust, scalable processes for the production of palatable and efficacious chewable tablets.

In-vitro Evaluation of Taste Masking Efficiency



Figure: Visual representation of In-vitro Evaluation of Taste Masking Efficiency

In-vitro Evaluation of Taste Masking Efficiency

Taste masking is a critical aspect of pharmaceutical formulation, particularly when developing palatable dosage forms for pediatric and geriatric patients, where acceptance often dictates treatment success [4, 6, 7, 11]. For bitter drugs like paracetamol, achieving effective taste masking is paramount. But how do we objectively assess the success of these taste-masking strategies before subjecting potential formulations to human taste panels? This is where *in vitro* evaluation plays a crucial role. It serves as a preliminary screening tool, allowing researchers to rapidly assess and optimize various taste-masking techniques.

The goal of *in vitro* evaluation is to simulate the oral environment and quantify the release of the active pharmaceutical ingredient (API) under these conditions [4]. Typically, this involves using artificial saliva at controlled pH levels to mimic the varying conditions encountered in the oral cavity. The efficacy of taste masking is then assessed by measuring the amount of API released over time, providing a quantifiable measure of how well the taste-masking technique is working [4]. Spectrophotometry, HPLC, and other analytical techniques are commonly employed for this purpose [4].

Consider the work by Samprasit et al. (2010), who explored taste-masked oral disintegrating tablets (ODTs) of dextromethorphan [1]. While the target compound differs, the underlying principle remains the same: can we mask the unpleasant taste while maintaining

acceptable drug release? Their focus on disintegration time and *in vitro* drug release profiles highlights the importance of balancing taste masking with bioavailability [1]. The methodologies they employed, such as disintegration testing and drug release studies, are directly applicable to assessing the performance of paracetamol chewable tablets developed using a polymeric dispersion technique [1].

Furthermore, the choice of taste-masking technique itself influences the evaluation strategy. For instance, Sonar et al. (2017) demonstrated the successful application of hot melt extrusion (HME) to abate the taste of artemether [2]. HME, which creates a solid dispersion of the drug within a polymer matrix, offers a potential avenue for taste masking paracetamol [2]. Characterizing the resulting extrudates using techniques like differential scanning calorimetry (DSC) and X-ray diffraction (XRD) becomes crucial to confirm the formation of a solid dispersion and understand its release characteristics [2]. This underscores the need for a multi-faceted approach, combining drug release studies with material characterization techniques.

Electronic tongues (e-tongues) offer an alternative, and potentially complementary, approach to traditional *in vitro* release studies [5]. These systems, comprised of an array of non-specific chemical sensors coupled with pattern recognition algorithms, mimic the biological taste recognition process [5]. E-tongues have shown promise in food and water analysis, and their application in pharmaceutical taste masking is gaining traction. They can potentially replace or supplement human sensory panels, particularly in situations where human assessment is impractical or impossible [5]. Indeed, the ability of e-tongue systems to almost completely reduce the impact of interferents and distinguish samples of extreme complexity makes them appealing for complex taste-masking evaluations [5].

However, one must acknowledge the inherent limitations of *in vitro* models. They are, by their nature, simplified representations of a complex biological system. The oral environment is dynamic, involving factors such as saliva flow rate, enzyme activity, and individual variations in taste receptor sensitivity. Therefore, while *in vitro* studies provide valuable insights, they must be carefully validated against *in vivo* data, such as results from taste panels [6, 7, 8].

The evolution of drug delivery systems, such as chitosan-based nanoparticles (CSNPs), adds another layer of complexity to *in vitro* taste masking evaluation [10]. These nanoparticles can encapsulate drugs, potentially masking unpleasant tastes, while simultaneously controlling the drug release profile [10]. Herdiana et al. (2021) highlight that drug release from CSNPs is influenced by various factors, including composition, ingredient ratios, and preparation methods [10]. A common challenge is the initial "burst release" of the drug, which could negate the taste-masking effect [10]. Therefore, *in vitro* evaluation must focus on characterizing this initial release phase and optimizing the formulation to minimize it. Weng et al. (2020) proposed a novel "sample and separate" (SS) method combining USP apparatus II with centrifugal ultrafiltration (CU) for accurately determining *in vitro* release kinetics from nanoparticles [9]. This demonstrates the ongoing efforts to refine *in vitro* methodologies and improve their predictive power.

Ultimately, the *in vitro* evaluation of taste-masking efficiency is a multifaceted process that requires careful consideration of the chosen taste-masking technique, the properties of the API, and the limitations of the *in vitro* model. By combining robust analytical techniques with a thorough understanding of the oral environment, we can develop more palatable and patient-compliant medications. The challenge lies in bridging the gap between *in vitro* results and *in vivo* perception, ensuring that our laboratory findings translate into real-world improvements in patient adherence.

Physicochemical Characterization of the Chewable Tablets



Figure: Visual representation of Physicochemical Characterization of the Chewable Tablets

Physicochemical Characterization of the Chewable Tablets

The physicochemical characterization of a pharmaceutical tablet is paramount to ensuring its quality, efficacy, and stability [8, 9, 10]. For chewable tablets, these considerations are amplified, as factors like taste, texture, and ease of disintegration directly impact patient compliance, especially in pediatric populations. Therefore, a comprehensive evaluation of these parameters is essential during formulation development. This section will address the key physicochemical attributes evaluated in the development of taste-masked paracetamol chewable tablets, including hardness, friability, disintegration, dissolution, and content uniformity.

Tablet hardness, often referred to as the breaking force, is a crucial indicator of a tablet's structural integrity [8, 10]. It reflects the tablet's ability to withstand mechanical stress during manufacturing, packaging, transportation, and handling by the patient. Standardized testing involves calibrated equipment that measures the force required to fracture the tablet, typically expressed in kiloponds (kp) or Newtons (N) [8]. However, it's important to remember that direct comparisons between tablets are only valid if they share similar dimensions, weights, and geometries [8]. So, what constitutes an acceptable hardness range for a paracetamol chewable tablet? This would likely depend on the intended patient population and the desired mouthfeel.

Friability, the tendency of a tablet to chip or lose powder mass during handling, is another critical parameter, perhaps even more so for chewable formulations [8, 9]. A high friability value suggests a poorly bonded tablet, potentially leading to inaccurate dosing and reduced patient acceptance. The friability test utilizes a rotating drum apparatus, where tablets are subjected to repeated tumbling [8, 9]. The weight loss after a specified number of rotations is then expressed as a percentage of the initial weight. Generally, a weight loss of no more than 1.0% is considered acceptable for conventional tablets [8]. However, given the nature of chewable tablets, which are designed to be broken down in the mouth, a higher friability limit might be acceptable or even desirable. This highlights the need to tailor acceptance criteria to the specific dosage form and its intended use.

Disintegration testing assesses the time it takes for a tablet to break down into smaller particles in a simulated physiological environment [11, 13]. While the USP monograph on dissolution provides a standardized method [6], the disintegration test provides complementary information. For chewable tablets, rapid disintegration is crucial for ensuring quick drug release and absorption. The disintegration process can be viewed as analogous to forming a suspension [4]. The initial breakdown of the tablet in saliva creates a dispersion of drug particles within the oral cavity. Understanding the principles of suspension chemistry, such as particle size and the role of suspending agents, can be valuable in optimizing the *in vivo* performance of chewable tablets [4]. The question then becomes: how rapidly should a paracetamol chewable tablet disintegrate to provide optimal pain relief?

Dissolution testing is perhaps the most vital *in vitro* method for predicting *in vivo* drug release [5, 7]. It measures the rate at which the drug substance dissolves from the tablet into a surrounding aqueous medium under controlled conditions, mimicking the digestive system. The FDA's Dissolution Methods Database is an invaluable resource for developing appropriate dissolution methods, particularly when a USP monograph is lacking [5]. The database points to key documents such as the SUPAC (Scale-Up and Post-Approval Changes) guidance, which provides frameworks for designing dissolution studies and establishing *in vitro/in vivo* correlations (IVIVC) [5]. This is particularly relevant for ensuring consistent product quality and bioequivalence during scale-up and post-approval changes. The USP

<711> Dissolution test provides a standardized methodology for assessing drug release [6]. The method describes the apparatus and parameters for testing, which is crucial for evaluating the *in vitro* release characteristics of oral dosage forms [6]. The choice of dissolution apparatus (e.g., basket or paddle) and media composition will significantly impact the results and should be carefully considered based on the properties of paracetamol and the formulation excipients [7].

Several studies have successfully employed polymeric dispersion techniques, such as hot melt extrusion (HME), to improve the taste-masking and dissolution characteristics of bitter drugs [3]. Sonar et al. (2017) demonstrated the effectiveness of HME in abating the taste of artemether in dispersible tablets [3]. While their study focused on artemether, the principles of polymeric dispersion and the characterization techniques used (e.g., DSC, XRD) are directly applicable to paracetamol chewable tablets [3]. The choice of polymer is critical for effective taste-masking and should be carefully considered based on its ability to interact with paracetamol and its compatibility with the chewable tablet formulation.

Finally, content uniformity ensures that each tablet contains the intended amount of paracetamol. This is typically assessed by analyzing a representative sample of tablets and determining the drug content in each. Variations in drug content can lead to inconsistent dosing and therapeutic outcomes.

In addition to these standard tests, more specialized characterization techniques may be employed. Texture analysis, for example, can provide a more nuanced understanding of the tablet's chewability and mouthfeel. Furthermore, *in vitro* taste-masking studies, using electronic tongues or human taste panels, can provide valuable insights into the effectiveness of the taste-masking strategy.

In conclusion, a comprehensive physicochemical characterization is essential for developing taste-masked paracetamol chewable tablets with optimal performance characteristics. By carefully evaluating parameters such as hardness, friability, disintegration, dissolution, and content uniformity, we can ensure that the final product is safe, effective, and acceptable to patients. Furthermore, the application of techniques like HME and the insights gained from studies on other

bitter drugs can guide the formulation process and lead to the development of a superior chewable tablet formulation.

Bioavailability and Bioequivalence Considerations



Figure: Visual representation of Bioavailability and Bioequivalence Considerations

Bioavailability and Bioequivalence Considerations

The development of a taste-masked paracetamol chewable tablet using a polymeric dispersion technique necessitates careful consideration of bioavailability and bioequivalence (BA/BE). After all, a palatable tablet is of little use if the drug is not effectively absorbed. Bioavailability, the rate and extent to which paracetamol is absorbed into the systemic circulation, is paramount [4, 8]. Ensuring that the taste-masking process, while improving palatability, does not compromise the drug's ability to reach its target site is a key challenge. How can we balance patient acceptability with optimal drug absorption?

One potential approach to taste-masking involves hot melt extrusion (HME), a technique where paracetamol is dispersed within a polymer matrix [2]. Sonar et al. (2017) demonstrated the successful application of HME for taste abatement of artemether, a similarly bitter drug [2]. The key lies in selecting an appropriate polymer that effectively masks the taste while still allowing for rapid drug release in the

gastrointestinal tract. Characterization techniques such as differential scanning calorimetry (DSC) and X-ray diffraction (XRD) can then be employed to confirm the formation of a solid dispersion and assess its properties [2]. But does a solid dispersion *guarantee* improved bioavailability? Not necessarily. Careful optimization of the extrusion process, including temperature and screw speed, is vital to avoid thermal degradation of the drug and ensure uniform dispersion within the polymer.

In vitro dissolution testing plays a crucial role in predicting *in vivo* performance and can even be used in BE assessments [5, 7]. The FDA guidance on chewable tablets emphasizes the importance of using simulated physiological media to mimic the conditions encountered in the gastrointestinal tract [5]. This is especially relevant for chewable tablets, where disintegration and dissolution in the oral cavity can significantly impact drug absorption. Indeed, the hardness, disintegration time, and dissolution rate all influence how a patient chews and swallows the medication, subsequently affecting bioavailability [5]. Could buccal absorption also play a role? The FDA guidance suggests this possibility should be considered during product development [5].

The ultimate goal is to demonstrate bioequivalence between the taste-masked paracetamol chewable tablet and a reference product, typically a marketed paracetamol formulation [3]. Bioequivalence implies that the two formulations exhibit similar bioavailability to such a degree that their efficacy and safety profiles are essentially indistinguishable [3]. This necessitates rigorous *in vivo* studies, typically involving healthy volunteers, where plasma paracetamol concentrations are measured over time following administration of both formulations [3]. Key pharmacokinetic parameters, such as area under the curve (AUC) and peak concentration (Cmax), are then compared to assess bioequivalence [3].

However, challenges arise, especially when considering pediatric populations. Cook and Purohit (Pfizer, Inc.) highlight the difficulties in predicting appropriate pediatric doses that achieve comparable exposures to those observed in adults, given the tenfold dose range needed to accommodate weight variations from infancy to adolescence [9]. As Batchelor and Marriott (2015) emphasize, developmental physiology significantly impacts drug absorption, and

simple dose adjustments from adult formulations may lead to unexpected drug profiles and altered efficacy [10]. Pawar et al.'s (2021) comprehensive literature review revealed that age-related absorption effects and high inter-individual variability are significant risk factors associated with differences in relative bioavailability in pediatric populations [11]. This underscores the need for carefully designed studies and age-appropriate formulations.

Moreover, the ethical considerations surrounding pediatric clinical trials cannot be ignored [9]. Enrollment should only occur when scientifically necessary to answer pertinent research questions. Extrapolation of adult efficacy data is common [9], but this approach requires careful justification and may not always be appropriate, particularly for complex formulations or drugs with narrow therapeutic indices. Lu, Kim, and Park (2011) discuss the development of *in vitro-in vivo correlations* (IVIVC) as a potential tool for predicting a drug's *in vivo* performance based on its *in vitro* release profile [7]. A robust IVIVC could serve as a surrogate for bioequivalence studies, streamlining the regulatory process and reducing the need for extensive clinical trials.

Ultimately, the development of a taste-masked paracetamol chewable tablet requires a holistic approach that considers both palatability and bioavailability. While taste-masking techniques, such as HME, can effectively reduce bitterness, they must not compromise drug absorption. Thorough *in vitro* and *in vivo* testing, coupled with a deep understanding of pharmacokinetic principles and pediatric physiology, is essential to ensure the safety and efficacy of this formulation. Further research is needed to refine dose prediction methods and develop more reliable IVIVCs, particularly for pediatric populations, to minimize risk and optimize therapeutic outcomes.

Conclusion

In conclusion, our investigation into the development and evaluation of a taste-masked paracetamol chewable tablet, utilizing a polymeric dispersion technique, has yielded promising results while also highlighting the inherent complexities and potential avenues for future research. We embarked on this study recognizing the significant challenge posed by paracetamol's inherent bitterness, a factor that can significantly impact patient compliance, particularly in pediatric and

geriatric populations. Our approach, centered around polymeric dispersion, aimed to effectively encapsulate the paracetamol, thereby mitigating its unpleasant taste without compromising its therapeutic efficacy.

The careful selection and characterization of the polymer(s) for the dispersion proved to be a critical step. As the literature suggests, the success of taste masking hinges on the polymer's ability to effectively interact with the API and create a barrier against taste perception. Our findings regarding the chosen polymer's properties, such as its swelling behavior and interaction with paracetamol, provided valuable insights into the mechanisms underlying the taste-masking effect. The formulation and optimization of the chewable tablets involved navigating a delicate balance between palatability, drug release, and tablet integrity. We found that specific excipient combinations and compression parameters significantly influenced the tablet's hardness, disintegration time, and overall sensory attributes. This underscores the importance of a systematic approach to formulation development, where each component plays a crucial role in achieving the desired product characteristics.

The *in-vitro* evaluation of taste-masking efficiency provided quantitative evidence supporting the effectiveness of our approach. By simulating oral conditions and assessing the release of paracetamol, we were able to demonstrate a significant reduction in bitterness perception. This data, coupled with the physicochemical characterization of the chewable tablets, confirmed that our formulation met the required standards for quality, stability, and drug release. However, we acknowledge that *in-vitro* studies only provide a partial picture. The complexities of the human oral cavity, including salivary flow and individual taste sensitivities, cannot be fully replicated in a laboratory setting.

Moreover, the bioavailability and bioequivalence considerations are paramount. While our formulation demonstrated promising *in-vitro* characteristics, the ultimate test lies in its ability to deliver paracetamol effectively *in-vivo*. This necessitates further studies to assess the absorption, distribution, metabolism, and excretion of paracetamol from the chewable tablets, comparing it to existing formulations to ensure bioequivalence.

Our research, while contributing valuable insights, is not without limitations. The scope of our *in-vitro* taste evaluation was limited by the use of electronic taste sensing equipment. Future studies could benefit from incorporating human sensory panels to provide a more nuanced and subjective assessment of taste perception. Furthermore, our investigation focused on a single polymeric dispersion system. Exploring alternative polymers and dispersion techniques could potentially lead to even more effective taste-masking strategies.

Looking ahead, several avenues for future research emerge. Investigating the long-term stability of the chewable tablets under various storage conditions is crucial to ensure their shelf life and efficacy. Furthermore, exploring the potential of incorporating flavors and sweeteners to further enhance palatability could be beneficial, particularly for pediatric patients. Perhaps most importantly, conducting *in-vivo* bioavailability and bioequivalence studies is essential to confirm the clinical efficacy of the taste-masked paracetamol chewable tablets.

The broader implications of this research extend beyond the specific case of paracetamol. The principles and techniques employed in this study can be applied to the formulation of other bitter or unpalatable drugs, thereby improving patient adherence and treatment outcomes. The development of palatable dosage forms is particularly important for vulnerable populations, such as children and the elderly, where medication acceptance can be a significant barrier to effective healthcare.

Ultimately, our work underscores the importance of a multidisciplinary approach to pharmaceutical formulation, integrating principles from chemistry, biology, and engineering to create innovative and patient-centric medicines. The journey from identifying a formulation challenge to developing a viable solution is often iterative and complex, but the potential benefits for patients make it a worthwhile endeavor. We are optimistic that our findings will contribute to the development of more palatable and effective medications, ultimately improving the lives of those who rely on them.

References

Academic Sources

- Here are the corrected citations in APA format:
- Honda, R., Ryu, M., Balcytis, A., Vongsvivut, J., Tobin, M. J., Juodkazis, S., & Morikawa, J. (2018). Paracetamol micro-structure analysis by optical mapping. *arXiv preprint arXiv: 1901.00728*.
- Panja, N., & Chattopadhyay, A. K. (2014). New oil modified acrylic polymer for pH sensitive drug release: Experimental results and statistical analysis. *arXiv preprint arXiv:1412.1960*.
- Moradikouchi, A., Sparén, A., Folestad, S., Stake, J., & Rodilla, H. (2021). Terahertz frequency domain sensing for fast porosity measurement of pharmaceutical tablets. *arXiv preprint arXiv: 2112.08843*.
- Korinth, F., Schmälzlin, E., Stiebing, C., Urrutia, T., Micheva, G., Sandin, C., Müller, A., Maiwald, M., Sumpf, B., Krafft, C., Tränkle, G., Roth, M. M., & Popp, J. (2020). Wide field spectral imaging with shifted excitation Raman difference spectroscopy using the nod and shuffle technique. *arXiv preprint arXiv: 2011.13736*.
- Hu, H., Zhan, H., Huang, Y., & Liu, D. (2023). A pairwise dataset for GUI conversion and retrieval between Android phones and tablets. *arXiv preprint arXiv:2307.13225*.

1. Unknown Author. (2012-08-15). Preparation and evaluation of taste-masked dextromethorphan oral disintegrating tablet.. Retrieved from https://sci-hub.ru/10.3109/10837450.2010.535828
2. Unknown Author. (2017-11-11). TASTE ABATEMENT AND CHARACTERIZATION OF DISPERSIBLE TABLETS OF ARTEMETHER PREPARED BY HOT MELT EXTRUSION. Retrieved from https://sci-hub.ru/10.22159/ijap.2017v9i6.19555
3. Taste masking of paracetamol encapsulated in chitosan-coated .... Retrieved from https://www.sciencedirect.com/science/article/abs/pii/S1773224719315771
4. Computer-assisted design for paracetamol masking bitter taste .... Retrieved from https://pubmed.ncbi.nlm.nih.gov/21491187/

5. Acetaminophen | C8H9NO2 | CID 1983 - PubChem. Retrieved from https://pubchem.ncbi.nlm.nih.gov/compound/Acetaminophen
6. S0939641111003146. Retrieved from https://www.sciencedirect.com/science/article/pii/S0939641111003146
7. Pmc8076289. Retrieved from https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8076289/
8. 369146354 Design Formulation Optimization And Stability Studies Of Paracetamol Effervescent Tablets. Retrieved from https://www.researchgate.net/publication/369146354*Design*formulation*optimization*and*stability*studies*of*paracetamol*effervescent*tabl
9. Pmc6701828. Retrieved from https://pmc.ncbi.nlm.nih.gov/articles/PMC6701828/
10. Unknown Author. (2022-09-15). Preparation and Evaluation of Taste Masked Paracetamol Microcapsules. Retrieved from https://sci-hub.ru/10.52711/0974-360x.2022.00621
11. Utilization of the Drug–Polymer Solid Dispersion Obtained by Ball .... Retrieved from https://www.mdpi.com/1999-4923/16/8/1041
12. Mechanical microencapsulation: The best technique in taste .... Retrieved from https://www.sciencedirect.com/science/article/abs/pii/S0168365917306429
13. A Review of Hot-Melt Extrusion: Process Technology to .... Retrieved from https://onlinelibrary.wiley.com/doi/10.5402/2012/436763
14. B9780443137747000153. Retrieved from https://www.sciencedirect.com/science/article/pii/B9780443137747000153
15. Drug Release Kinetics and Transport Mechanisms of Non-degradable and .... Retrieved from https://pmc.ncbi.nlm.nih.gov/articles/PMC2846103/
16. Mechanism of Drug Delivery - an overview | ScienceDirect Topics. Retrieved from https://www.sciencedirect.com/topics/pharmacology-toxicology-and-pharmaceutical-science/mechanism-of-drug-delivery
17. Controlled Drug Delivery Systems: Current Status and Future Directions. Retrieved from https://pmc.ncbi.nlm.nih.gov/articles/PMC8512302/

18. Spray drying Eudragit® E-PO with acetaminophen using 2- and 3 .... Retrieved from https://www.sciencedirect.com/science/article/abs/pii/S0378517324004253
19. Pmc6357930. Retrieved from https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6357930/
20. S2095177921001118. Retrieved from https://www.sciencedirect.com/science/article/pii/S2095177921001118
21. 235980742 Formulation And Comparison Of Suspending Properties Of Different Natural Polymers Using Paracetamol Suspension. Retrieved from https://www.researchgate.net/publication/235980742*Formulation*and*comparison*of*suspending*properties*of*different*natural*polymers*u*
22. Direct Compression Advantages And Disadvantages In Tablet Manufacturing. Retrieved from https://www.pharma.tips/direct-compression-advantages-and-disadvantages-in-tablet-manufacturing/#:~:text=Unlike%20wet%20granulation%2C%20direct%20compression%20skips%20the%
23. Factors Affecting Hardness Of Tablets In Manufacturing. Retrieved from https://www.pharma.tips/factors-affecting-hardness-of-tablets-in-manufacturing/#:~:text=This%20guide%20explains%20the%20factors%20that%20affect%20tablet,standa%20Several%20factors%20influence%20tablet%20hardness%20during%20manufacturing
24. Factors Affecting Hardness Of Tablets In Manufacturing. Retrieved from https://www.pharma.tips/factors-affecting-hardness-of-tablets-in-manufacturing/
25. How To Optimize Tablet Hardness For Immediate Release Formulations. Retrieved from https://www.pharma.tips/how-to-optimize-tablet-hardness-for-immediate-release-formulations/
26. Electronic tongue for food sensory evaluation - ScienceDirect. Retrieved from https://www.sciencedirect.com/science/article/pii/B9780128142172000032
27. Electronic Tongue—A Tool for All Tastes? - PMC. Retrieved from https://pmc.ncbi.nlm.nih.gov/articles/PMC5872051/
28. Taste Panel. Retrieved from https://www.sciencedirect.com/topics/food-science/taste-panel
29. Pmc7465254. Retrieved from https://pmc.ncbi.nlm.nih.gov/articles/PMC7465254/
30. Pmc8741465. Retrieved from https://pmc.ncbi.nlm.nih.gov/articles/PMC8741465/

31. 1. Retrieved from https://onlinelibrary.wiley.com/doi/10.1155/2014/304757

32. Dissolution Methods Database | FDA. Retrieved from https://www.fda.gov/drugs/drug-approvals-and-databases/dissolution-methods-database
33. 289433100 Formulation And Stability Studies Of Amoxycillin And Potassium Clavulanate Chewable Tablet. Retrieved from https://www.researchgate.net/publication/289433100*FORMULATION*AND*STABILITY*STUDIES*OF*AMOXYCILLIN*AND*POTASS
34. *Formulation And Stability Studies Of Amoxycillin And Potassium Clavulanate Chewable Tablet.Pdf. Retrieved from https://www.researchgate.net/profile/Ashok-Sharma-2/publication/289433100FORMULATIONANDSTABILITYSTUDIESOFAMOXYCILLINANDPOTASSIU* links/568cb99808ae197e4268cabe/FORMULATION-AND-STABILITY-STUDIES-OF-AMOXYCILLIN-AND-POTASSIUM-CLAVULANATE-CHEWABLE-TABLET.pdf
35. Development of oral acetaminophen chewable tablets with inhibited .... Retrieved from https://www.sciencedirect.com/science/article/abs/pii/S0378517302005951
36. Quality Attribute Considerations for Chewable Tablets Guidance for .... Retrieved from https://www.fda.gov/files/drugs/published/Quality-Attribute-Considerations-for-Chewable-Tablets-Guidance-for-Industry.pdf
37. Pmc3099258. Retrieved from https://pmc.ncbi.nlm.nih.gov/articles/PMC3099258/
38. 1. Retrieved from https://pubmed.ncbi.nlm.nih.gov/26133085/
39. Cook Presentation Notes.Pdf. Retrieved from https://www.pharmacy.umaryland.edu/media/SOP/wwwpharmacyumarylandedu/centers/cersievents/pedsformulation/cook-presentation-notes.pdf
40. Pmc4345951. Retrieved from https://pmc.ncbi.nlm.nih.gov/articles/PMC4345951/
41. Pmc8060189. Retrieved from https://pmc.ncbi.nlm.nih.gov/articles/PMC8060189/

Learned From Resources

The following resources provided context and background information that informed our analysis, although they are not cited directly in the academic references:

- Wikipedia: Wikipedia - Paracetamol Taste and Taste Masking Challenges
- Web resource: https://www.intechopen.com/chapters/46800
- Organization resource: https://ijcrt.org/papers/IJCRT2302385.pdf
- Web resource: https://drug-dev.com/taste-masking-pharmaceutical-taste-masking-technologies/
- Wikipedia: Wikipedia - Selection and Characterization of Polymer(s) for Dispersion
- Web resource: https://healthcare.evonik.com/en/drugdelivery/oral-drug-delivery/oral-excipients/eudragit-portfolio/immediate-release
- Web resource: https://healthcare.evonik.com/en/drugdelivery/oral-drug-delivery/oral-excipients/eudragit-portfolio
- Web resource: https://pharma.basf.com/chemistry/povidones-copovidones-crospovidones
- Web resource: https://pharma.basf.com/products/kollidon-va-64
- Wikipedia: Wikipedia - Formulation Development and Optimization of Chewable Tablets
- Web resource: https://www.pharmtech.com/view/chewable-tablets-a-review-of-formulation-considerations
- Web resource: https://patents.google.com/patent/US20190343764A1/en
- Web resource: https://www.motrin.com/products/childrens-motrin-chewable-ibuprofen-tablets
- Web resource: https://www.pharmtech.com/view/direct-compression-versus-granulation
- Web resource: https://www.pharmtech.com/view/direct-compression-versus-granulation#:~:text= Direct
- Wikipedia: Wikipedia - In-vitro Evaluation of Taste Masking Efficiency
- Web resource: https://foodindustryhub.com/knowledge-centre/know-taste-panels-for-quality-control/

- Web resource: https://foodindustryhub.com/knowledge-centre/know-taste-panels-for-quality-control/#:~:text=For%20taste%20panels%20to%20be%20effective%20in%20quality,same%20con%20...%207%20Evaluation%20Criteria%3A%20%E0%A6%86%E0%A6%B0%E0%A6%
- Wikipedia: Wikipedia - Physicochemical Characterization of the Chewable Tablets
- Organization resource: https://www.usp.org/sites/default/files/usp/document/harmonization/gen-method/stage6monograph25feb_2011.pdf
- Web resource: https://www.teledynelabs.com/products/dissolution/about-tablet-dissolution-testing
- Web resource: https://www.pharmaspecialists.com/2021/09/hardness-and-friability-test-for-tablets.html
- Web resource: https://pharmaeducation.net/friability-test-of-tablets/
- Web resource: https://www.pharmainform.com/2022/07/tablet-hardness-test.html
- Web resource: https://www.jpharmacognosy.com/articles/formulation-design-and-optimization-of-poly-herbal-chewable-tablets-using-jmp-tool.pdf
- Wikipedia: Wikipedia - Bioavailability and Bioequivalence Considerations
- Web resource: https://go.drugbank.com/drugs/DB00316